Biocon share news, announcements and annual reports
NSE: BIOCONBSE: 532523Pharmaceuticals & BiotechnologyMid Cap
Biocon Limited · Face value ₹5 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Apr 2004
Last close ₹351.80down ₹0.10 (0.03%)BSE ₹352.00
Share price at the NSE close on 30 Oct 2026. Previous close ₹351.90.
30 Oct: open ₹352.70, high ₹355.50, low ₹348.70
52-week range of traded prices to 30 Oct 2026
₹318.40Low, 23 Oct 2026₹447.15High, 16 Jul 2026
- Next results date: the board meets on 4 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹57,333 Cr173rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 115.75
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹399 crore of one-off items, the largest of them in the quarter to Dec 2025.
- 64.09
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 1.68
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.14%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 1.8%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹399 crore of one-off items, the largest of them in the quarter to Dec 2025.
- 3.2%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 2.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.40
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 20,63,63747.1% delivered
Biocon share news and announcements
1,771 announcements, routine notices left out, newest first. Page 30 of 36.
Jun 2015
May 2015
Apr 2015
30 Apr · Updates
Mar 2015
27 Mar · Dividend
Company will pay Interim Dividend within 30 days from March 26, 2015.27 Mar · Corporate action
Company has fixed Record Date as April 10, 2015 for the purpose of declaration Interim dividend27 Mar · Dividend
Board of Director vide its Circular resolution dated March 26, 2015 has approved the payment of Interim Dividend at a rate of 100% i.e. (Rs 5/- per share) for the Financial Year 2014-15.
Jan 2015
12 Jan · Legal
Exchange had sought clarification from Biocon Limited with respect to an announcement dated January 12, 2015, wherein the Company informed the Exchange that M/s Silver Leaf Oak (Mauritius) Limited has assigned its rights and obligations for acquisition of 10% stake in Syngene International Limited ('Syngene') to M/s IVF Trustee Company Private limited ('IVF'), a fund advised by India Value Fund Advisors. Biocon Research limited, a wholly owned subsidiary of the Company has concluded such sale to IVF. Post conclusion of the above, Biocon and BRL jointly hold 85.54% stake in Syngene. The Company has clarified as follows: a) The amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division of the listed entity during the last financial year; Company Response: Syngene International Limited is a subsidiary of the Company and the details of the turnover, income and networth are disclosed in the Statement under Section 212 of the Companies Act, 1956. The same formed part of our Annual Report (Page 156). The statement is attached herewith for your ready reference. b) Date on which the agreement for sale has been entered into; Company Response: The Agreement was entered into on September 18, 2014 (at which time the intimation to the exchange was made). On January 9, 2015, Silver Leaf Oak (Mauritius) Limited assigned its interest in the contract to IVF Trustee Company Private Limited. Post the said assignment, the consideration was received on January 12, 2015 by Biocon Research Limited, which has been intimation to the Exchange today. c) Consideration received from such sale/disposal; Company Response:The consideration was mentioned by us in the earlier communication to the Stock Exchange. Biocon Research Limited transferred 10% stake in Syngene at an enterprise valuation of Rs 3,800 Crores (the consideration thereby being Rs 380 Crores for the 10% stake) d) Whether the transaction would fall within related party transactions? If yes, whether the same is done at arm s length; Company Response: The transaction has been made with an independent part (ie. IVF Trustee Company Private Limited).12 Jan · Legal
Exchange has sought clarification from Biocon Limited with respect to an announcement dated January 12, 2015, regarding press Release dated September 18, 2014, Company informed the Exchange that M/s Silver Leaf Oak (Mauritius) Limited has assigned its rights and obligations for acquisition of 10% stake in Syngene International Limited ('Syngene') to M/s IVF Trustee Company Private limited ('IVF'), a fund advised by India Value Fund Advisors. Biocon Research limited, a wholly owned subsidiary of the Company has concluded such sale to IVF. Post conclusion of the above, Biocon and BRL jointly hold 85.54% stake in Syngene . On basis of above Company is required to clarify following: a) The amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division of the listed entity during the last financial year; b) Date on which the agreement for sale has been entered into c) Consideration received from such sale/disposal; d) Whether the transaction would fall within related party transactions? If yes, whether the same is done at arm s length. Response from the Company is awaited.5 Jan · Board meeting
Inter alia, to approve and take on record the unaudited financial results of the Company for the quarter ended December 31, 2014.
Dec 2014
15 Dec · Legal
Exchange has sought clarification from Biocon Limited with respect to recent news item captioned Biocon Plans to Set up Mfg Unit in Vizag. In this regard, Exchange has advised the Company to provide clarification/confirmation on the news item in detail including the following: "a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company are aware of any information that has not been announced to the Exchanges under clause 36 of the Listing Agreement". The response from the Company is awaited.
Nov 2014
Oct 2014
1 Oct · Board meeting
Inter alia, to approve and take on record the unaudited financial results of the Company for the quarter and half year ended September 30, 2014.
Sep 2014
Aug 2014
Jul 2014
30 Jul · Disclosure of Voting Pattern - Clause 35A
30 Jul · Dividend
Dividend of Rs. 5/- per equity share approved by the members of the Company at the Annual General Meeting held on July 25, 2014 will be paid out on July 31, 2014.1 Jul · Board meeting
Inter alia, to approve and take on record the unaudited financial results of the Company for the quarter ended June 30, 2014.
Jun 2014
19 Jun · Meeting
Annual General Meeting is scheduled to be held on July 25, 2014.18 Jun · Meeting
Company has fixed Book Closure from July 12, 2014 to July 25, 2014 for the purpose of Annual General Meeting & Declaration of Dividend.
Apr 2014
25 Apr · Dividend
Board of Directors at its meeting held on April 24, 2014 has recommended a final dividend of Rs 5/- per share (i.e. 100%) for the financial year 2013-14. The declaration of dividend is subject to shareholders' approval at the ensuing Annual General Meeting of the company to be held during July 2014.15 Apr · News Verification
News Verification : The media had reports that "Bonus Buzz in Biocon". The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Biocon Limited has vide its letter inter-alia stated, "At the outset would like to deny the news item."2 Apr · Board meeting
Inter alia, to: (a) Approve and take on record the audited financial results for the year ended on March 31, 2014. (b) Consider recommendation for payment of dividend, if any, for the year 2013-2014.